Fortis Healthcare Management Guidance Tracker

Management reiterated guidance for hospital EBITDA margins to trend towards 18-20% in coming quarters, despite Q1 margin of 15.2%.

Management reiterated its target of achieving 20% EBITDA margin for the hospital business in the next financial year, driven by occupancy ramp-up and cost control.

Management expects to achieve 20% EBITDA margin for the hospital business by year-end, driven by occupancy improvement and cost optimization.

Over the next 3-4 years, as brownfield bed expansions ramp up, management aims for 25% EBITDA margin.

Hospital operating EBITDA margin expected to improve by ~200bps in FY25, building on FY24's 18.6% (hospital) and 18.4% consolidated.

Management reiterated guidance for hospital business EBITDA margins to exceed 20% for the full year, despite Q1 margin of 18.5% impacted by one-offs and mix.

Management reaffirmed guidance of 200 bps margin expansion for the hospital business for the full year, factoring in initial losses from Manesar.

Agilus aims to achieve 25-26% EBITDA margins in 15-18 months, driven by operating leverage and cost optimization.

Management expects hospital EBITDA margin to reach 20.5% for the full year FY25, with a medium-term target of 25%.

Agilus Diagnostics is expected to deliver adjusted EBITDA margin of 21-22% for FY25.

Management guided for ~200bps margin expansion in the hospital business for FY26, similar to the improvement seen in FY25.

Management reiterated guidance of 200 bps margin expansion for the hospital business in FY26, supported by case mix improvement and operational efficiencies.

Management expects diagnostics EBITDA margins to remain in the 22-23% range for the full year, with Q2 typically stronger.

Management indicated possibility of higher margin improvement than guided at the beginning of the year, driven by ramp-up of new units.

Agilus CFO guided margins to be around 23-24% for the full year, based on H1 performance of 24%.

Management expects ARPOB to grow 4-5% for the full year, moderating from Q1's 12% growth due to base effects.

Management expects hospital revenue to grow 14-15% in FY26, with ARPOB growth of 5-6% and volume growth making up the balance.

Management expects occupancy to reach 70% over the medium term, supported by bed additions and ramp-up.

The company expects to exit FY24 with occupancy around 70%, despite seasonal fluctuations and new bed additions.

Management expects occupancy to recover to ~70% in Q4 FY24 and next year, driven by seasonal recovery and international patient rebound.

ARPOB growth expected to moderate to 4-5% in medium term from 10.8% in FY24, driven by 2-2.5% price increases and case mix improvement.

Management expects Agilus to consolidate during FY25 and return to industry-level growth in FY26, driven by brand recovery and network expansion.

The Manesar facility, currently at INR 5 crore monthly revenue, is expected to break even at INR 9 crore per month by Q1 FY26.

Agilus expects to return to industry-level growth of 8-10% by Q2 FY26, driven by volume growth.

Management targets double-digit revenue growth for Agilus in FY26, with EBITDA margin (net) around 23%, moving towards 25% in a couple of years.

Agilus expects revenue growth to trend in the high single-digits over the next few quarters, moving to early double-digits in 6-8 quarters.

Company added 550 operational beds in H1 FY26 and expects full-year addition of 400-500 beds.

Management expects ARPOB growth of 5-6% in second half, driven by mix improvement and robotic surgeries.

Management expects ARPOB to grow 4-5% annually, driven by case mix and price increases.

Planned bed additions of 300-400 per year, primarily brownfield expansions in NCR, Mulund, and Kolkata.

Brownfield expansions at Mulund, Anandapur, BG Road, and Ludhiana will add approximately 250 beds in the current financial year.

Total brownfield bed pipeline increased to 1,800 beds, including new projects at Mohali (400 beds) and Shalimar Bagh, plus Manesar (350 beds) over 2.5-3 years.

Brownfield bed expansion plan to add ~2,200 beds, with ~710 beds expected in FY25, including the Manesar acquisition.

Includes 50 beds each at Faridabad and Kalyan, 100 beds at Manesar (Q2), 100 beds at Kolkata (Q1), and beds at BG Road (Q2).

The acquired Manesar facility is expected to start operations in the ongoing quarter, initially with 100 beds, ramping up to full capacity over 18 months.

Management expects to add 350-400 beds in FY26 through brownfield expansions at Noida, FMRI, Anandapur, and BG Road.

Management plans to add approximately 1,000 beds in FY26 through brownfield expansions at Noida, Faridabad, Manesar, FMRI, and BG Road.

Fortis plans to add approximately 900 beds in FY26, including the recently acquired Shrimann Superspecialty Hospital, with about half becoming operational in the current fiscal.

Targeting over 400 brownfield beds next year, primarily from FMRI expansion (200 beds) and other facilities.

Management expects to finalize the put option (due Oct 2024) by August-September 2024, with options including IPO revival or buyout via debt/equity.

Agilus plans to spend approximately INR 50 crore on rebranding expenses this fiscal year, which will be treated as one-off costs.

IHH may infuse fresh equity via preferential allotment to strengthen balance sheet for growth.

Annual capex includes maintenance and growth capex for both years, supporting brownfield expansions and equipment upgrades.